4.8 Article

E3 ubiquitin ligase Cullin-5 modulates multiple molecular and cellular responses to heat shock protein 90 inhibition in human cancer cells

出版社

NATL ACAD SCIENCES
DOI: 10.1073/pnas.1322412111

关键词

protein quality control; protein degradation; ERBB2; BRAF; oncoprotein

资金

  1. Cancer Research UK [C309/A8274, C309/A11566, C309/A8140]
  2. Cancer Research UK [11566] Funding Source: researchfish

向作者/读者索取更多资源

The molecular chaperone heat shock protein 90 (HSP90) is required for the activity and stability of its client proteins. Pharmacologic inhibition of HSP90 leads to the ubiquitin-mediated degradation of clients, particularly activated or mutant oncogenic protein kinases. Client ubiquitination occurs via the action of one or more E3 ubiquitin ligases. We sought to identify the role of Cullin-RING family E3 ubiquitin ligases in the cellular response to HSP90 inhibition. Through a focused siRNA screen of 28 Cullin-RING ligase family members, we found that CUL5 and RBX2 were required for degradation of several HSP90 clients upon treatment of human cancer cells with the clinical HSP90 inhibitor 17-AAG. Surprisingly, silencing Cullin-5 (CUL5) also delayed the earlier loss of HSP90 client protein activity at the same time as delaying cochaperone dissociation from inhibited HSP90-client complexes. Expression of a dominant-negative CUL5 showed that NEDD8 conjugation of CUL5 is required for client degradation but not for loss of client activity or recruitment of clients and HSP90 to CUL5. Silencing CUL5 reduced cellular sensitivity to three distinct HSP90 inhibitors, across four cancer types driven by different protein kinases. Our results reveal the importance of CUL5 inmultiple aspects of the cellular response to HSP90 inhibition.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Correction Biochemistry & Molecular Biology

Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases (vol 38, pg 5905, 2020)

Chi Zhang, Simon R. Stockwell, May Elbanna, Robin Ketteler, Jamie Freeman, Bissan Al-Lazikani, Suzanne Eccles, Alexis De Haven Brandon, Florence Raynaud, Angela Hayes, Paul A. Clarke, Paul Workman, Sibylle Mittnacht

ONCOGENE (2020)

Article Oncology

A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic Cancer

Charlotte K. Milton, Annette J. Self, Paul A. Clarke, Udai Banerji, Federica Piccioni, David E. Root, Steven R. Whittaker

MOLECULAR CANCER THERAPEUTICS (2020)

Article Multidisciplinary Sciences

Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer

Sheelagh Frame, Chiara Saladino, Craig MacKay, Butrus Atrash, Peter Sheldrake, Edward McDonald, Paul A. Clarke, Paul Workman, David Blake, Daniella Zheleva

PLOS ONE (2020)

Article Biochemistry & Molecular Biology

A PI3K-and GTPase-independent Rac1-mTOR mechanism mediates MET-driven anchorage-independent cell growth but not migration

Alexia Hervieu, Sara Farrah Heuss, Chi Zhang, Rachel Barrow-McGee, Carine Joffre, Ludovic Menard, Paul Andrew Clarke, Stephanie Kermorgant

SCIENCE SIGNALING (2020)

Article Medicine, Research & Experimental

Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma

Evon Poon, Tong Liang, Yann Jamin, Susanne Walz, Colin Kwok, Anne Hakkert, Karen Barker, Zuzanna Urban, Khin Thway, Rhamy Zeid, Albert Hallsworth, Gary Box, Marli E. Ebus, Marco P. Licciardello, Yordan Sbirkov, Glori Lazaro, Elizabeth Calton, Barbara M. Costa, Melanie Valenti, Alexis De Haven Brandon, Hannah Webber, Nicolas Tardif, Gilberto S. Almeida, Rossitza Christova, Gunther Boysen, Mark W. Richards, Giuseppe Barone, Anthony Ford, Richard Bayliss, Paul A. Clarke, Johann De Bono, Nathanael S. Gray, Julian Blagg, Simon P. Robinson, Suzanne A. Eccles, Daniella Zheleva, James E. Bradner, Jan Molenaar, Igor Vivanco, Martin Eilers, Paul Workman, Charles Y. Lin, Louis Chesler

JOURNAL OF CLINICAL INVESTIGATION (2020)

Review Biochemistry & Molecular Biology

Alternative systems for misfolded protein clearance: life beyond the proteasome

Harvey E. Johnston, Rahul S. Samant

Summary: Protein misfolding plays a crucial role in ageing-related frailty and disease pathology. Understanding how to maintain protein homeostasis and how protein quality control systems fail with environmental stress and ageing remains an exciting area of research with potential implications for healthy ageing strategies.

FEBS JOURNAL (2021)

Article Multidisciplinary Sciences

Native mass spectrometry analyses of chaperonin complex TRiC/CCT reveal subunit N-terminal processing and re-association patterns

Miranda P. Collier, Karen Betancourt Moreira, Kathy H. Li, Yu-Chan Chen, Daniel Itzhak, Rahul Samant, Alexander Leitner, Alma Burlingame, Judith Frydman

Summary: The study characterized recombinant human TRiC (hTRiC) using mass spectrometry techniques, revealing post-translational processing of its subunits. Interestingly, some subunits can promiscuously re-assemble into dimers with non-canonical contacts. CCT5 was found to be the most stable subunit and engaged in the greatest number of non-canonical dimer pairings.

SCIENTIFIC REPORTS (2021)

Article Chemistry, Analytical

Solvent Precipitation SP3 (SP4) Enhances Recovery for Proteomics Sample Preparation without Magnetic Beads

Harvey E. Johnston, Kranthikumar Yadav, Joanna M. Kirkpatrick, George S. Biggs, David Oxley, Holger B. Kramer, Rahul S. Samant

Summary: Complete and reproducible extraction of protein is crucial for proteome analysis. Solvent precipitation SP3 (SP4) is proposed as an alternative method, which captures protein aggregates by centrifugation instead of magnetism. SP4 provides equivalent or higher protein yields and improved reproducibility. It also recovers more low-solubility and transmembrane proteins, offering higher recovery rates.

ANALYTICAL CHEMISTRY (2022)

Meeting Abstract Hematology

Multiomics Analysis of IMiD/CELMoD Resistant Multiple Myeloma Models Uncovers Novel and Targetable Vulnerabilities in the SREBP Lipid Synthesis Pathway

Sarah A. Bird, Amy Barber, Fernando J. Sialana, Marco P. Licciardello, Harvey Che, Habib Bouguenina, Yura Grabovska, Enze Liu, Yakinthi Chrisochoidou, Shannon Martin, Jyoti Choudhary, Brian A. Walker, Ian Collins, Paul Clarke, Charlotte Pawlyn

Article Biochemical Research Methods

Native Size-Exclusion Chromatography-Based Mass Spectrometry Reveals New Components of the Early Heat Shock Protein 90 Inhibition Response Among Limited Global Changes

Rahul S. Samant, Silvia Batista, Mark Larance, Bugra Ozer, Christopher I. Milton, Isabell Bludau, Estelle Wu, Laura Biggins, Simon Andrews, Alexia Hervieu, Harvey E. Johnston, Bissan Al-Lazikhani, Angus I. Lamond, Paul A. Clarke, Paul Workman

Summary: The molecular chaperone HSP90 plays a role in stabilizing client proteins involved in oncogenesis and malignant progression. Inhibitors of HSP90 have diverse effects on the proteome, but previous studies have mainly focused on total protein levels rather than protein complex alterations. This study used SEC-MS to characterize early changes in native protein complexes after treatment with the HSP90 inhibitor tanespimycin in colon adenocarcinoma cells. The study identified novel HSP90 inhibitor-modulated proteins and provides a resource for further research in HSP90 pharmacology. The data is available via ProteomeXchange (identifier: PXD033459).

MOLECULAR & CELLULAR PROTEOMICS (2023)

Article Chemistry, Medicinal

HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies

A. Elisa Pasqua, Swee Y. Sharp, Nicola E. A. Chessum, Angela Hayes, Loredana Pellegrino, Michael J. Tucker, Asadh Miah, Birgit Wilding, Lindsay E. Evans, Carl S. Rye, N. Yi Mok, Manjuan Liu, Alan T. Henley, Sharon Gowan, Emmanuel De Billy, Robert te Poele, Marissa Powers, Suzanne A. Eccles, Paul A. Clarke, Florence I. Raynaud, Paul Workman, Keith Jones, Matthew D. Cheeseman

Summary: CCT251236, a potent chemical probe, was developed through a cell-based high-throughput screen to discover inhibitors of the transcription factor HSF1 that supports malignancy. The compound was optimized to mitigate P-glycoprotein efflux and eventually led to the design of a clinical candidate, CCT361814/NXP800 22, which demonstrated tumor regression in a human ovarian adenocarcinoma xenograft model. It has now progressed to phase 1 clinical trial as a potential treatment for refractory ovarian cancer and other malignancies.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Meeting Abstract Oncology

Discovery and validation of biomarkers to support clinical development of NXP800: A first-in-class orally active, small-molecule HSF1 pathway inhibitor

P. Workman, P. A. Clarke, R. Te Poele, M. Powers, G. Box, E. De Billy, A. De Haven Brandon, A. Hallsworth, A. Hayes, H. McCann, S. Sharp, M. Valenti, F. I. Raynaud, S. A. Eccles, M. Cheeseman, K. Jones

EUROPEAN JOURNAL OF CANCER (2022)

Article Biochemistry & Molecular Biology

Evolution of kinase polypharmacology across HSP90 drug discovery

Albert A. Antolin, Paul A. Clarke, Ian Collins, Paul Workman, Bissan Al-Lazikani

Summary: This study identified and systematically characterized the kinase cross-pharmacology of representative HSP90 inhibitors using computational and experimental methods, revealing unique off-target kinase pharmacology of certain clinical candidates. It was also shown that polypharmacology evolved during optimization to discover luminespib, with hit, leads, and clinical candidate having different profiles. The study recommends early computational and experimental characterization of polypharmacology in drug discovery projects to uncover new opportunities for multi-target drug design.

CELL CHEMICAL BIOLOGY (2021)

暂无数据